Why was Japan’s vaccine rollout slow compared with other countries? Experts have pointed out the stringent regulations of Japan’s approval process for new drugs, which require conducting clinical trials at home even in times of emergency — like the COVID-19 pandemic.

But during a radio program on Tuesday, vaccine rollout minister Taro Kono revealed that U.S. drugmaker Pfizer Inc. had included more than 100 Japanese residents in the United States in its clinical trials last year, since Japan was not among the countries where it conducted trials. The pharmaceutical company conducted trials in the U.S., Germany, Turkey, South Africa, Brazil and Argentina on more than 40,000 participants.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.